EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication

Area of Science:

• Pharmacovigilance and Reproductive Toxicology
• Epidemiology of Congenital Anomalies
• Drug Safety in Pregnancy

Background:

• Inadequate information exists regarding medication safety during pregnancy.
• A systematic approach is needed to identify potential risks of medications to fetal development.
• Congenital anomaly registries are crucial for monitoring drug-associated birth defects.

Purpose of the Study:

• To develop and evaluate a signal detection methodology for identifying unusual associations between medications and congenital anomalies.
• To utilize data from European congenital anomaly registries for routine safety monitoring.
• To identify specific medication-anomaly associations for further investigation.

Main Methods:

• Analysis of the EUROmediCAT database, including 14,950 malformed fetuses/babies with first-trimester medication exposures (1995-2011).
• Comparison of odds for specific medication exposures against all other anomalies using 40,385 medication-anomaly combinations.
• Application of Simes multiple testing procedure with a 50% false discovery rate (FDR) to identify statistically significant associations, prioritizing those with >2 cases.

Main Results:

• Fifty-two specific medication-anomaly associations were identified.
• After exclusions, 39 associations were selected for further investigation.
• These included well-established teratogens such as valproic acid (2 cases) and insulin for maternal diabetes (14 cases).

Conclusions:

• The EUROmediCAT database enables systematic analysis to identify potential drug-related congenital anomaly risks.
• The developed methodology can generate a manageable set of associations for validation.
• Effective teratogen detection relies on exposure frequency, risk level, and teratogenic specificity.